Rebecca Taub - Feb 22, 2022 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role: Chief Medical Officer, President, R&D ** As attorney-in-fact for Reporting Person, Director
Signature: /s/ Brian J. Lynch **
Stock symbol: MDGL
Transactions as of: Feb 22, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/24/2022, 07:12 PM
Next filing: Aug 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MDGL	Stock Option (Right to Buy)	Award	$0	+61.5K		$0.00	61.5K	Feb 22, 2022	Common Stock	61.5K	$87.09	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

Remarks:

Chief Medical Officer, President, R&D ** As attorney-in-fact for Reporting Person